Q1 2026 Elutia Inc Earnings Call Transcript
Key Points
- Elutia Inc (ELUT) advanced its NXT-41 regulatory program with productive interactions with the FDA, increasing confidence in the planned NXT-41x submission.
- The company successfully brought its automated manufacturing platform online, supporting a target gross margin in excess of 80% at scale.
- Direct surgeon engagement confirmed a $1.5 billion US market opportunity in breast reconstruction, with significant unmet needs due to high post-operative infection rates.
- Elutia Inc (ELUT) ended the quarter with a strong balance sheet, holding $36.5 million in cash and escrow.
- The company has prior success with its first-generation product, EluPro, which was sold to Boston Scientific for $88 million, providing confidence in its current technology and commercialization strategy.
- SimpliDerm revenue decreased to $2.1 million from $2.6 million in the prior year period.
- The company reported a net loss of $7.5 million for the quarter, compared to a net loss of $3.9 million in the prior year period.
- Adjusted EBITDA was a loss of $4.4 million, up from a loss of $2.8 million a year ago.
- The increase in net loss was driven by non-cash items and other expenses, specifically the revaluation of warrant liabilities.
- Elutia Inc (ELUT) is still in the process of divesting its SimpliDerm and Cardiovascular product lines, which could impact future revenue streams.
Thank you for standing by and welcome to Elutia's first-quarter 2026 earnings conference call. (Operator Instructions) I would now like to hand the call over to Bernadine Cherniak. Please go ahead.
Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the first quarter ended March 31, 2026. A copy of the press release is available on the company's website.
Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Federal Securities laws, which are pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements include without limitation,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
